|Day's range||2.7400 - 3.5500|
Gilead Sciences (GILD) closed the most recent trading day at $76.08, moving -0.16% from the previous trading session.
SANTA MONICA, Calif., June 06, 2023--Kite, a Gilead Company (Nasdaq: GILD), today announces findings from the largest real-world analysis to date of Tecartus® (brexucabtagene autoleucel) in patients with relapsed or refractory mantle cell lymphoma (R/R MCL), which show that outcomes of Tecartus therapy had consistent high complete response (CR) and overall response rates (ORR), regardless of type of prior treatment, including: Bruton's tyrosine kinase inhibitor (BTKi), bendamustine or autologous
Gilead (GILD) and Arcus announce data from the interim analysis of the mid-stage ARC-7 study on domvanalimab in the NSCLC study.
FOSTER CITY, Calif., June 05, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) today announced longer-term overall survival (OS) results from the Phase 3 TROPiCS-02 study evaluating Trodelvy® (sacituzumab govitecan-hziy) versus comparator chemotherapy (physicians’ choice of chemotherapy, TPC) in patients with HR+/HER2- (IHC0, IHC1+, IHC2+/ISH-) metastatic breast cancer who received endocrine-based therapies and at least two chemotherapies. In this exploratory analysis, Trodelvy demonstrated a clinical
SANTA MONICA, Calif., June 05, 2023--Kite, a Gilead Company (Nasdaq: GILD), today announces detailed results from the overall survival (OS) analysis of the landmark Phase 3 ZUMA-7 study of Yescarta® (axicabtagene ciloleucel [axi-cel]) CAR T-cell therapy compared with historical standard of care (SOC) as initial treatment in the curative setting for patients with relapsed or refractory large B-cell lymphoma (R/R LBCL). Yescarta is the first treatment in nearly 30 years to demonstrate a significan
FOSTER CITY, Calif., & HAYWARD, Calif., June 03, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) today announced updated results from an interim analysis of the ARC-7 study in patients with first-line, metastatic non-small cell lung cancer (NSCLC) with PD-L1 tumor proportion score (TPS) ≥50% without epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) mutations. ARC-7 is the first Phase 2, randomized, open-label study evaluating the comb
Three Motley Fool contributors identified dividend stocks that should be easy buy decisions for investors. Here's why they think Bristol Myers Squibb (NYSE: BMY), Gilead Sciences (NASDAQ: GILD), and Pfizer (NYSE: PFE) are investments you can make in June without any hesitation. David Jagielski (Bristol Myers Squibb): Bristol Myers Squibb has been paying dividends for more than 90 consecutive years.
FOSTER CITY, Calif. & SANTA MONICA, Calif., June 01, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, will present 17 abstracts from its industry-leading cell therapy portfolio and growing blood cancer pipeline at the upcoming 2023 European Hematology Association (EHA) Annual Congress being held in Frankfurt, Germany, June 8-11, and virtually June 14-15.
Gilead (GILD) obtains positive opinion for the use of Veklury in COVID-19 patients with severe renal impairment, including those on dialysis, from the European Medicines Agency's CHMP.
FOSTER CITY, Calif., May 26, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) granted a positive opinion for the use of Veklury® (remdesivir) in COVID-19 patients with severe renal impairment, including those on dialysis. The European Commission (EC) will review the CHMP recommendation and, if adopted, Veklury will become the first and only authorized antiviral COVID-19 treatment that
FOSTER CITY, Calif., May 25, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conference:
Here's why three Motley Fool contributors think that AbbVie (NYSE: ABBV), Gilead Sciences (NASDAQ: GILD), and Johnson & Johnson (NYSE: JNJ) are relatively safe stocks to buy if a recession is declared this year. Prosper Junior Bakiny (AbbVie): It may be hard to believe that AbbVie is a safe stock right now.
FOSTER CITY, Calif. & SANTA MONICA, Calif., May 17, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, will present 30 abstracts during the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting. These data reinforce the strength of Gilead and Kite Oncology’s transformative science in hard-to-treat cancers.
FOSTER CITY, Calif., May 16, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Cindy Perettie will join the company as Executive Vice President of Kite, a Gilead Company, overseeing the cell therapy business, and will become a member of Gilead’s senior leadership team, effective May 30.
Arcus (RCUS) surges as it expands its previous research collaboration with partner Gilead, to focus on developing therapies for inflammatory diseases.
FOSTER CITY, Calif., & HAYWARD, Calif., May 15, 2023--Gilead Sciences, Inc. (Nasdaq:GILD) and Arcus Biosciences, Inc. (NYSE:RCUS) today announced that the companies have expanded the previously announced research collaboration focused on oncology to include therapies for the treatment of inflammatory diseases. The expanded collaboration builds upon Gilead’s growing presence in inflammatory disease and serves as a step towards broadening Arcus’ capabilities and portfolio beyond oncology and into
You may know of Gilead Sciences (NASDAQ: GILD) because of its blockbuster coronavirus treatment Veklury. In fact, the S&P 500 has outperformed Gilead over the past five years. Gilead has struggled to consistently deliver annual revenue growth ever since its hepatitis C portfolio's revenue reached a peak back in 2015.
FOSTER CITY, Calif., May 09, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the acquisition of all outstanding shares of XinThera, a privately held biotech company in San Diego. The acquisition complements Gilead’s existing clinical development priorities by adding additional pipeline assets for well-validated targets in oncology and inflammation.
Here is your VIP list of Pro Picks for the week, offered exclusively to InvestingPro subscribers: a hand-picked selection of S&P 500 stocks that InvestingPro awarded a high financial health score of at least 2.75 out of 5.00.
Let's look at two great dividend stocks to consider buying before the economy worsens: Gilead Sciences (NASDAQ: GILD) and Amgen (NASDAQ: AMGN). Gilead Sciences is a biotech company with a particular focus on developing HIV medicines. It has helped Gilead Sciences' revenue stay afloat as the company failed to earn approval for important candidates.
Gilead Sciences (NASDAQ: GILD) has a bright future ahead with HIV treatment Sunlenca obtaining approval from the Food and Drug Administration last year and cancer drug Trodelvy continuing to show strong growth. Why has Gilead Sciences stock struggled? The simple reason for Gilead's woes is that the business has had trouble generating growth.
FOSTER CITY, Calif., May 04, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for Hepcludex® (bulevirtide) for the treatment of adults with chronic HDV and compensated liver disease, and recommended granting full Marketing Authorisation (MA) that is no longer subject to specific obligations. Bulevirtide was initially granted conditional marketing authoris
FOSTER CITY, Calif., May 01, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences:
Jacquie, please go ahead. The speakers on today's call will be our chairman and chief executive officer, Daniel O'Day; our chief commercial officer, Johanna Mercier; our chief medical officer, Merdad Parsey; and our chief financial officer, Andrew Dickinson.
Gilead's (GILD) Q1 earnings and sales miss estimates due to lower Veklury sales.